Tuesday, July 10, 2012
OncoSec Medical Inc., of San Diego, received Investigational Review Board (IRB) approval at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center for a Phase II trial evaluating OncoSec's OMS ElectroImmunotherapy to treat cutaneous T-cell lymphoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.